S

SoftOx Solutions AS
OSE:SOFTX

Watchlist Manager
SoftOx Solutions AS
OSE:SOFTX
Watchlist
Price: 0.0154 NOK 10% Market Closed
Market Cap: 30m NOK
Have any thoughts about
SoftOx Solutions AS?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-0.5
Current
-3.2
Median
13.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.5
=
Enterprise Value
26.7m NOK
/
EBITDA
-56.3m NOK
All Countries
Close
Market Cap EV/EBITDA
NO
SoftOx Solutions AS
OSE:SOFTX
30m NOK -0.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
753.9B USD 48.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 20.5
US
Johnson & Johnson
NYSE:JNJ
343.8B USD 11.3
US
Merck & Co Inc
NYSE:MRK
252.9B USD 10.5
CH
Roche Holding AG
SIX:ROG
214.1B CHF 10.5
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP 169.8
CH
Novartis AG
SIX:NOVN
178.3B CHF 9.6
US
Pfizer Inc
NYSE:PFE
152.6B USD 10.6
EBITDA Growth EV/EBITDA to Growth
NO
S
SoftOx Solutions AS
OSE:SOFTX
Average EV/EBITDA: 459.7
Negative Multiple: -0.5
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
42%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.5
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A